乳酸脱酶抑制剂:对抗衰老和纤维化的一个有希望的候选者
Wenxin Luo1, Guanru Wang2, Honglin Li2
1State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China; Department of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu, China.
European journal of medicinal chemistry
|November 24, 2025
概括
乳酸脱酶 (LDH) 对于新陈代谢和氧化还原平衡至关重要. 针对LDH的抑制剂 (LDHi) 对衰老和纤维化有希望,但需要改进的输送和特异性.
科学领域:
- 生物化学 生物化学
- 代谢途径 代谢途径
- 酶学 是一种酶学.
背景情况:
- 乳酸脱酶 (LDH) 是糖解中的一个关键酶,对于细胞氧化还原稳定和NAD+再生至关重要.
- LDH异型的多样化结构使得有针对性的抑制 (LDHi) 能够进行代谢调节.
- 在衰老和纤维化中,LDH影响代谢重编程,影响衰老和细胞外基质沉积.
研究的目的:
- 审查LDH结构,功能和老化和纤维化中的作用.
- 从化学生物学角度评估现有的天然和合成LDH抑制剂 (LDHi).
- 提出开发更有效,更安全的临床使用LDHi的策略.
主要方法:
- 关于LDH结构,功能和抑制的综合文献综述.
- 自然和合成LDHi作用机制的化学生物学分析.
- 评估LDHi在衰老和纤维性疾病中的应用和限制.
主要成果:
- LDH与糖解,氧化还原平衡,衰老和纤维化有关.
- 现有的LDHi表现出多样化的抑制机制,但在组织特异性和毒性方面面临挑战.
- 产药和有针对性的输送系统是为了克服目前的局限性而提出的.
结论:
- 抑制LDH是一种对抗衰老和纤维化疾病的有前途的治疗策略.
- 改进的LDHi设计,专注于特异性和安全性,对于临床翻译至关重要.
- 先进的输送系统,如基于纳米粒子的方法,可以提高LDHi的疗效,减少系统性毒性.
相关概念视频
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
217
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
217
01:46Electron Transport Chain: Complex I and II
18.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
18.4K
01:19The Effect of Aging on Tissues
3.1K
Several body functions deteriorate with age. The external signs of aging are easily identifiable. For example, the skin becomes dry, less elastic, and thins out, forming wrinkles. The skin of the face begins to appear looser due to a decrease in the levels of elastic and collagen fibers in the connective tissue. Additionally, melanin production in the hair follicle decreases with age, resulting in gray hair. Moreover, the senses of sight and hearing decline, so glasses and hearing aids may...
3.1K
01:37Mitochondria
19.5K
Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
19.5K
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
186
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
186
01:23Dipeptidyl Peptidase 4 Inhibitors
566
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
566